Revenue ($USD) : $14,240,000,000
R&D spend : $1,414,000,000
Employees : 48,000
Fiscal year end : 12/31/2023
CEO : Michael Mahoney

www.bostonscientific.com

Boston Scientific has been enjoying a banner year in 2024. As of the writing of this description in mid-August, its stock was up more than 31% year-to-date, and the company used its second-quarter earnings report to once again raise its sales guidance. The cardiovascular, endoscopy, neuromodulation, and urology device company — which seeks to positively disrupt the general surgery space — now expects 13.5–14.5% sales growth for 2024. Recent highlights for Boston Scientific include more positive data for its Farapulse pulsed field ablation system for treating AFib. Boston Scientific announced in January that Farapulse won FDA approval to treat drug-refractory, recurrent, symptomatic, paroxysmal AFib. In July, it announced Farapulse approval in China. Boston Scientific also recently announced plans for its $1.16 billion acquisition of Silk Road Medical, which develops products designed to prevent stroke in patients with carotid artery disease. Boston Scientific is also in the process of acquiring Axonics and its neuromodulation systems for treating urinary and bowel dysfunction; the nearly $3.7 billion deal is presently expected to close during the second half of 2024 pending review by the U.S. Federal Trade Commission. Late in 2023, Boston Scientific made an initial upfront payment of $850 million to purchase Relievant Medsystems, enhancing its position in the chronic pain management market. –CN

MORE ON MDO: Catheter design was key for the Boston Scientific Farapulse pulsed field ablation system